05/16/22 4:45 PMNasdaq : OCDX Ortho Clinical Diagnostics Shareholders Approve Quidel TransactionOrtho Clinical Diagnostics Holdings plc (NASDAQ: OCDX) (“Ortho” or the “Company”), one of the world’s largest pure-play in vitro diagnostics (IVD) companies, today announced that based on a preliminary vote count by its proxy solicitor, OrthoRHEA-AIpositive
05/04/22 4:05 PMNasdaq : OCDX Ortho Clinical Diagnostics Reports First Quarter 2022 ResultsSolid Revenue Performance Drives Financial Results Highlights • Core revenue declined (0.9%) to $495.0 million, and grew 0.6% in constant currency and 4.2% excluding CoV-2 assay sales, which was a 4% headwind • Growth, excluding CoV-2 assay sales, was driven by Americas, EMEA, and ASPAC regionsRHEA-AIneutral
04/26/22 8:59 AMNasdaq : OCDX covid-19Ortho Clinical Diagnostics Recognized with Fifth Prestigious Edison Award for Highly Accurate COVID-19 SolutionOrtho Clinical Diagnostics (NASDAQ: OCDX), one of the world's largest pure-play in vitro diagnostics (IVD) companies, has been recognized with a prestigious Gold 2022 Edison Award for its VITROS ®RHEA-AIvery positive
04/20/22 4:14 PMNasdaq : OCDX conferencesOrtho Clinical Diagnostics to Report First Quarter 2022 Results on May 4, 2022Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX), one of the world’s largest pure-play in vitro diagnostics companies, today announced it will report results for its first quarter 2022 ended April 3, 2022, after the market close onRHEA-AIneutral
03/09/22 8:55 AMNasdaq : OCDX Ortho Clinical Diagnostics Wins Bronze Stevie® Award for Customer Service and SupportOrtho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play in vitroRHEA-AIpositive
02/16/22 4:05 PMNasdaq : OCDX earningsOrtho Clinical Diagnostics Reports Fourth Quarter and Fiscal Year 2021 ResultsStrong Revenue Growth Drives Financial Results Highlights • Fourth quarter Core revenue grew 3.5% to $518.9 million, or 4.3% in constant currency and 8.0% excluding CoV-2 assay sales • Fiscal year Core revenue grew 16.1% to $2.01 billion, or 14.6% in constant currency and 15.7% excluding CoV-2RHEA-AIvery positive
01/24/22 8:00 AMNasdaq : OCDX Ortho Clinical Diagnostics Holdings Plc (“Ortho”): Notice of UK Court Scheme Directions HearingFurther to the joint announcement by Ortho and Quidel Corporation (“ Quidel ”) on December 23, 2021 of the signing of a definitive business combination agreement, Ortho announces that, as a preliminary procedural step in the process of implementingRHEA-AIpositive
01/06/22 4:50 PMNasdaq : OCDX earningsOrtho Clinical Diagnostics Announces Preliminary Financial Results for Fourth Quarter and Fiscal Year 2021Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) (the “Company”), one of theRHEA-AIpositive
01/03/22 8:00 AMNasdaq : OCDX conferencesOrtho Clinical Diagnostics to Participate in the 40th Annual J.P. Morgan Healthcare ConferenceOrtho Clinical Diagnostics Holdings plc (Nasdaq: OCDX), one of the world’s largest pure-play in vitro diagnostics (IVD) companies, today announced that members of its management team are scheduled to participate in the 40 th Annual J.P. MorganRHEA-AIneutral
12/23/21 7:00 AMNasdaq : QDEL, OCDX acquisitionQuidel Corporation Signs Definitive Agreement to Acquire Ortho Clinical DiagnosticsBrings together highly complementary diagnostic portfolios with world-class technologies and platforms spanning high-throughput systems to near-patient and at-home testing. Provides Quidel’ s expansive point-of-care diagnostics portfolio with access to Ortho’ s broad global reach across 130- plus countries, accelerating growth for Quidel’ s...RHEA-AIvery positive